Depression: Pharmaceutical and Therapeutics Latest Pipeline Guide

This press release was originally issued by SBWire

Pune, Maharashtra — (SBWIRE) — 10/13/2022 — HTF Market Intelligence has published a new 668-page research report on the stock ‘Depression – Pipeline Review, H2 2022’ with detailed analysis, forecasts and strategies. The market study is segmented by key region which is accelerating the marketing. The study is a perfect blend of qualitative and quantitative market data collected and validated mainly through primary data and secondary sources. This section also provides the scope of different segments and applications that can potentially influence the market in the future. Detailed information is based on current trends and historical milestones.

Download Sample PDF Report >>>

Depression – Pipeline Review, H2 2022
Depression is a mood disorder that causes a persistent feeling of sadness and loss of interest. Signs and symptoms include trouble sleeping, including insomnia or oversleeping, changes in appetite, anxiety, restlessness or restlessness, and physical problems, such as aches back pain or headaches. Treatment includes antidepressants, mood stabilizers, or antipsychotics.

Report Highlights:

Global Markets Direct Depression’s latest pharmaceutical and healthcare pipeline guide – Pipeline Review, H2 2022, provides comprehensive information on treatments in development for depression (central nervous system), with analysis by stage of development , drug target, mechanism of action (MoA), route of administration (RoA) and type of molecule. The guide covers the therapeutic’s descriptive pharmacological action, its full research and development history, and the latest news and press releases.

The Depression (Central Nervous System) Pipeline Guide also reviews key players involved in therapeutic development for depression and features dormant and discontinued projects. The guide covers therapeutics in development by companies/universities/institutes, molecules developed by companies in pre-registration, filing rejected/withdrawn, phase III, phase II, phase I, IND/CTA filed, preclinical, discovery and stages unknowns are 6, 2, 16, 36, 42, 4, 86, 22 and 5 respectively. Similarly, the portfolio of Universities in Phase II, Preclinical and Discovery includes 1, 13 and 7 molecules respectively.

The Depression (Central Nervous System) Pipeline Guide assists in identifying and tracking emerging market players and their portfolios, enhances decision-making abilities, and assists in creating effective counter-strategies to gain competitive advantage. The guide is built using data and information from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings , investor presentations, and featured press releases from company/academic sites and industry-specific third-party sources. Additionally, various dynamic tracking processes ensure that the latest developments are captured in real time.


– The pipeline guide provides an overview of the global Depression (Central Nervous System) therapeutic landscape.
– The Pipeline Guide reviews pipeline therapies for Depression (Central Nervous System) by companies and universities/research institutes based on information from company and industry specific sources.
– The pipeline guide covers pipeline products based on multiple development stages ranging from pre-registration to discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for pipeline products, which include product description, descriptive license and collaboration details, R&D dossier, MoA, and other development activities.
– The pipeline guide reviews the major companies involved in the therapy of depression (central nervous system) and calls on all their major and minor projects.
– The pipeline guide rates treatments for depression (central nervous system) based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
– The pipeline guide encapsulates all dormant and abandoned pipeline projects.
– The pipeline guide reviews the latest news related to pipeline therapies for depression (central nervous system)

Reasons to buy:

– Acquire strategically important competitor information, analysis and insights to formulate effective R&D strategies.
– Recognize emerging players with a potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapies under development for Depression (Central Nervous System).
– Classify potential new customers or partners into the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and the most promising therapies in the pipeline.
– Formulate corrective measures for pipeline projects by understanding Depression (Central Nervous System) pipeline depth and focus of indication therapeutics.
– Develop and design licensing and out-licensing strategies by identifying potential partners with the most attractive projects to enhance and expand business potential and reach:.
– Adjust the therapeutic portfolio by recognizing abandoned projects and understand from know-how what drove them out of the pipeline.

Companies mentioned in the report:
Acadie Pharmaceutical Inc.
Adam Sp Zoo
Addex Therapeutics Ltd.
Aequus Pharma Inc.
Asion Biotechnologies Inc
Alkermes Plc
Allergan AG
Amorsa Therapeutic Inc
Anavex Life Sciences Corp.
Angelini Group
Antheia Inc
Asulon Therapeutics Inc
Atai Life Sciences S.A.
Avanir Pharmaceuticals Inc.
Avicanna Inc.

Depression – Overview
Depression – Therapeutic Development
Depression – Therapeutic assessment
Depression – Companies involved in therapeutic development
Depression – Drug Profiles
Depression – Dormant projects
Depression – Discontinued Products
Depression – Product Development Milestones


Buy this report @

Contact us:
CRAIG FRANCIS (Public Relations and Marketing Manager)
[email protected]
Phone: +1 (434) 299-0043

For more information on this press release, visit: